China syndrome? Phase II wins for Cue in CSU, stock melts down

Cue Biopharma Inc. is gearing up for a phase IIb/III study in chronic spontaneous urticaria (CSU, or hives), as well as a phase II in food allergy, after scoring in the mid-stage trial with CUE-221 in moderate to severe CSU.